Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …

The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

Importance Non–small cell lung cancer (NSCLC) with uncommonEGFRmutations is a rare
subgroup, composing 14% of allEGFRmutations. Objective To determine the usefulness of …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …

Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …

EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200
distinct mutations. The implications of mutational subtype for both prognostic and predictive …